The recent circular from ICMR proposes an accelerated development pathway for the BBV152 COVID vaccine. It is clear from the letter that even the preclinical development of the vaccine is not complete as yet, and even patient enrolment for Phase-1… Continue Reading →
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
https://www.nature.com/articles/s41467-020-16256-y